Standard Operating Procedure for Evaluating Freeze-Drying Parameters in Injectable Development
| Department | Formulation & Development |
|---|---|
| SOP No. | SOP/SIM/118/2025 |
| Supersedes | SOP/SIM/118/2022 |
| Page No. | Page 1 of 13 |
| Issue Date | 18/06/2025 |
| Effective Date | 20/06/2025 |
| Review Date | 18/06/2026 |
1. Purpose
To outline the process for evaluating, optimizing, and validating freeze-drying (lyophilization) parameters during the formulation development of sterile injectable products.
2. Scope
This SOP is applicable to all injectable products requiring lyophilization during development, including parenteral vials and dual-chamber systems.
3. Responsibilities
- Formulation
Scientist: Designs and conducts freeze-drying cycle trials.
Lyophilization Specialist: Operates lyophilizer and records data.
QA Department: Verifies data, protocol approvals, and documentation.
4. Accountability
The Head of Product Development is accountable for scientific design, and Head QA is accountable for procedural compliance.
5. Procedure
5.1 Pre-Trial Preparations
- Review physicochemical properties of formulation such as eutectic point, collapse temperature, and residual moisture limits.
- Verify lyophilizer calibration and mapping status.
- Prepare protocol for freeze-drying evaluation (Annexure-1).
5.2 Cycle Design
- Design preliminary freeze-drying cycle with stages including freezing, primary drying, and secondary drying.
- Define shelf temperature and chamber pressure for each stage.
- Use thermocouples and pressure gauges for internal monitoring.
5.3 Execution of Trial Cycles
- Prepare formulation in lyophilization vials under aseptic conditions.
- Run trial batches under defined cycle parameters.
- Document cycle time, temperature profiles, and vacuum levels.
5.4 Post-Cycle Evaluation
- Evaluate cake appearance, reconstitution time, pH, assay, and residual moisture (KF analysis).
- Perform leak test, sterility, and particulate matter testing.
- Compare parameters across multiple cycles to finalize optimal conditions.
5.5 Documentation
- Compile Freeze-Drying Trial Report (Annexure-2).
- Update Freeze-Drying Cycle Master Record (Annexure-3) upon finalization.
6. Abbreviations
- KF: Karl Fischer
- QA: Quality Assurance
- PD: Product Development
7. Documents
- Freeze-Drying Evaluation Protocol – Annexure-1
- Freeze-Drying Trial Report – Annexure-2
- Cycle Master Record – Annexure-3
8. References
- FDA Guidance on Lyophilization of Injectable Products
- USP <1118> Monitoring Devices—Time, Temperature, and Humidity
9. SOP Version
Version: 2.0
10. Approval Section
| Prepared By | Checked By | Approved By | |
|---|---|---|---|
| Signature | |||
| Date | |||
| Name | |||
| Designation | Formulation Scientist | QA Executive | Head QA |
| Department | Formulation Development | Quality Assurance | Quality Assurance |
11. Annexures
Annexure-1: Freeze-Drying Evaluation Protocol
Defines objectives, formulation details, cycle parameters, equipment, and controls.
Annexure-2: Freeze-Drying Trial Report
Summarized results including cake evaluation, reconstitution profile, residual moisture, assay, and other tests.
Annexure-3: Cycle Master Record
Approved lyophilization cycle to be used for further development and scale-up.
Revision History
| Revision Date | Revision No. | Details | Reason | Approved By |
|---|---|---|---|---|
| 10/08/2022 | 1.0 | Initial SOP | Development of lyophilized injectable formulation | Head QA |
| 18/06/2025 | 2.0 | Updated with structured cycle evaluation procedure | Alignment with regulatory practices | Head QA |